In the case of Glycogen storage disorder II, this enzyme Glycogn lysosomal acid alpha-glucosidase encoded by Glycoogen gene GAAwhich breaks down Adaptogen holistic healing into glucose Glycogen storage disorder use as a cellular Glycogen storage disorder Glyclgen. They reported on a young girl with phosphorylase kinase deficiency of Glydogen liver that was Glycogen storage disorder with autosomal recessive inheritance. GSD I is an inherited genetic disorder which causes the deficiency of one of the enzymes that work together to help the body break down the storage form of sugar glycogen into glucose, which the body uses to keep blood sugar stable when a person is not eating. Disclosure: Hajira Basit declares no relevant financial relationships with ineligible companies. New insights in the field of muscle glycogenoses. Patient and parent education about the dietary modifications and frequency of feeding is of utmost importance in optimizing the clinical outcomes for patients affected with these diseases.

Glycogen storage disorder -

The doctor may order blood tests and possibly a liver or muscle biopsy so that samples can be tested for enzyme levels to help determine if a child has GSD. There is currently no cure for GSD. After diagnosis, children with GSD are usually cared for by several specialists, including specialists in endocrinology and metabolism.

Specific dietitians with expertise in this disease should be involved. Depending on what type of GSD your child has, treatment typically focuses on promoting their growth and development and maintaining a healthy level of glucose in the blood.

Typically, doctors recommend small, frequent meals throughout the day. The meals should be low in sugar to prevent glycogen from building up in the liver. Uncooked cornstarch can help maintain a healthy blood-sugar level.

In some cases, doctors may recommend a nasogastric tube or gastrostomy G tube that delivers a continuous supply of nutrition while the child is sleeping. Children with GSD IV may need a liver transplant if the disease progresses to cirrhosis or liver failure.

The Glycogen Storage Diseases Program treats children and adults with known glycogen storage diseases. Learn more about Glycogen Storage Diseases Program. The Division of Gastroenterology, Hepatology and Nutrition offers care for children with GI, liver, and nutritional problems.

Learn more about Gastroenterology, Hepatology and Nutrition. Breadcrumb Home Conditions Glycogen Storage Disease. What is glycogen storage disease? What are the types of GSD? The most common types of GSD include: Glycogen storage disease type I GSD I , also known as von Gierke disease, accounts for about 25 percent of all children with GSD.

What are the risks of GSD? Each type of GSD carries specific risks. Other risks include: gout, a type of arthritis adenomas, tumors of the liver that are usually benign non-cancerous inflammatory bowel disease type 1b dental problems recurring infections type 1b pulmonary hypertension Infants with type III GSD III may have low blood sugar and excess fat in their blood.

Children with this type of GSD are also at risk for: slow growth and short stature muscle weakness Infants with Type IV GSD IV may not have low blood sugar, but they can develop early complications.

Product Editorial Subscription Options Subscribe Sign in. Learn how UpToDate can help you. Select the option that best describes you. View Topic. Font Size Small Normal Large. Overview of inherited disorders of glucose and glycogen metabolism.

Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share. View in. Language Chinese English.

These symptoms are especially noticeable in infants. Since people with GSD I are able to store glucose as glycogen but unable to release it normally, stores of glycogen build up in the liver over time and cause it to swell. The liver is able to perform many of its other functions normally, and there is no evidence of liver failure.

The kidneys also become enlarged because of increased glycogen storage. Children born with GSD I typically exhibit growth failure, chronic hunger, fatigue, irritability, an enlarged liver, and a swollen abdomen. Blood tests may indicate low blood sugar concentration and higher than normal levels of lipids and uric acid.

GSD I is an inherited genetic disorder which causes the deficiency of one of the enzymes that work together to help the body break down the storage form of sugar glycogen into glucose, which the body uses to keep blood sugar stable when a person is not eating.

Children with GSD I are usually diagnosed between 4 and 10 months of age. Testing will most likely include blood tests, imaging tests such as ultrasound to measure the liver and kidneys, and possibly a genetic test or liver biopsy. The treatment of type I glycogen storage disease is focused on correcting the metabolic changes in the body and promoting the growth and development of the child.

A combination of uncooked cornstarch mixed in water, soy formula, or soy milk is often recommended. Cornstarch is digested slowly, so it provides a steady release of glucose in between feedings. Current treatments consist of providing small, frequent feedings during the day.

Most doctors agree that certain sugars should be restricted, but the degree of restriction is still debated. In some cases, an overnight tube feeding, typically via a naso-gastric tube, is required to provide a continuous delivery of glucose.

Glycogen storage disorder has two classes Glycoben cause: genetic and environmental. Genetic GSD is storabe by any inborn Carb counting and meal planning of carbohydrate metabolism Glycogen storage disorder Glycoven enzymes or transport proteins Glycogrn in these processes. In livestock, environmental GSD is caused by intoxication with the alkaloid castanospermine. However, not every inborn error of carbohydrate metabolism has been assigned a GSD number, even if it is known to affect the muscles or liver. For example, phosphoglycerate kinase deficiency gene PGK1 has a myopathic form.

Video

Understanding Glycogen Storage Disease Type 1b and its impacts.

Glycogen storage disorder -

gov website belongs to an official government organization in the United States. gov website. Share sensitive information only on official, secure websites.

Glycogen storage disease type VII GSDVII is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells.

A lack of glycogen breakdown interferes with the function of muscle cells. There are four types of GSDVII. They are differentiated by their signs and symptoms and the age at which symptoms first appear.

The classical form of GSDVII is the most common form. Its features usually appear in childhood. This form is characterized by muscle pain and cramps, often following moderate exercise; strenuous exercise can lead to nausea and vomiting.

During exercise, muscle tissue can be abnormally broken down, releasing a protein called myoglobin. This protein is processed by the kidneys and released in the urine myoglobinuria. If untreated, myoglobinuria can damage the kidneys and lead to kidney failure.

Some people with the classical form of GSDVII develop high levels of a waste product called uric acid in the blood hyperuricemia because the damaged kidneys are unable to remove uric acid effectively. Affected individuals may also have elevated levels of a molecule called bilirubin in the blood that can cause yellowing of the skin and whites of the eyes jaundice.

Individuals with classical GSDVII often have elevated levels of an enzyme called creatine kinase in their blood.

This finding is a common indicator of muscle disease. Infants with the severe infantile form of GSDVII have low muscle tone hypotonia at birth, which leads to muscle weakness myopathy that worsens over time.

Affected infants have a weakened and enlarged heart cardiomyopathy and difficulty breathing normally. Individuals with this form of GSDVII usually do not survive past their first year of life. In the late-onset form of GSDVII, myopathy is typically the only feature. The muscle weakness appears in adulthood, although some individuals have difficulty with sustained exercise starting in childhood.

The weakness generally affects the muscles closest to the center of the body proximal muscles. The hemolytic form of GSDVII is characterized by hemolytic anemia, in which red blood cells are broken down undergo hemolysis prematurely, causing a shortage of red blood cells anemia.

People with the hemolytic form of GSDVII do not experience any signs or symptoms of muscle pain or weakness related to the disorder. GSDVII is thought to be a rare condition; more than cases have been described in the scientific literature.

The effects of the disease are apparent very early in childhood. Clinical trials are research studies that test how well new medical approaches work in people. Before an experimental treatment can be tested on human subjects in a clinical trial, it must have shown benefit in laboratory testing or animal research studies.

The most promising treatments are then moved into clinical trials, with the goal of identifying new ways to safely and effectively prevent, screen for, diagnose, or treat a disease. Speak with your doctor about the ongoing progress and results of these trials to get the most up-to-date information on new treatments.

Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications.

Start your search here to find clinical trials that need people like you. Glycogen Storage Disease Type 1 von Gierke. What is Liver Disease? How Many People Have Liver Disease? Facts at-a-Glance Also known as von Gierke disease , is a more severe form of Glycogen Storage Disease.

All Glycogen Storage diseases together affect fewer than 1 in 40, persons in the United States. Information for the Newly Diagnosed What are the symptoms of GSD I?

What causes GSD I? How is GSD I diagnosed? Fanconi-Bickel disease is a rare GSD caused by a GLUT2 deficiency due to a mutation in the SLC2A2 gene. This leads to increased glycogen storage and hepatomegaly.

As mentioned above, glycogen is a branched polymer. While glycogen phosphorylase works well at removing glucose from alpha- 1,4 -linkages, it does not work at branch points. Branch points are alpha-1,6 linkages. GSD type II is unique among GSDs because it is also classified as a lysosomal storage disease LSD.

Lysosomal storage diseases are caused by a missing or nonfunctional lysosomal enzyme. In the case of GSD II, this enzyme is lysosomal acid alpha-glucosidase encoded by the gene GAA , which breaks down glycogen into glucose for use as a cellular energy source.

Mutation in the GAA gene results in the toxic accumulation of glycogen in lysosomes. The true incidence of metabolic diseases is difficult to determine given the lack of uniform, universal screening at birth.

Individual incidence of specific GSD types is further complicated due to overlap in symptoms and the lack of standardized specific testing in most areas of the world. A study evaluating the incidence of inborn errors of metabolism in British Columbia in the s reported that the incidence of these diseases was approximately 30 cases per live births.

Approximately 2. As stated above, glycogen is the stored form of glucose and is composed of long polymers of 1,4 linked glucose with branch points via 1,6 linked glucose molecules. When these physiologic functions are defective, hypoglycemia, hepatomegaly, muscle cramps, exercise intolerance, and weakness develops.

Some disorders also affect the myocardial tissue and can lead to cardiomyopathy and cardiac conduction defects. In GSD type 1, for example, failure of glycogenolysis in the liver results in increased lactic acid production lactic acidosis due to the intracellular accumulation of glucosephosphate, which stimulates the glycolytic pathway.

GSDs are a diverse set of rare inborn errors of carbohydrate metabolism that can have variable phenotypic presentation even within the same GSD type.

Obtaining a family pedigree is useful in establishing the mode of inheritance. Most GSDs show an autosomal recessive inheritance, but a few GSD type IX show an x-linked inheritance.

Patients with a defect in hepatic glycogen metabolism usually present with fasting hypoglycemia and ketosis. Their symptoms improve with glucose administration. Patients with a defect in skeletal muscle glycogen metabolism present with fatigue and exercise intolerance after short periods of moderate-intense exercise.

In rare cases, progressive weakness may be reported. This, however, is usually limited to GSD type 0, II, and IV. In rare instances, GSD type III, V, and VII can present with weakness rather than muscle cramps and, over time, develop fixed weakness.

Anthropometric measurements should be obtained and graphed in all patients with GSDs to assess the overall growth pattern. Short stature or poor linear growth, especially in a child with hypoglycemia, should warrant workup for glycogen storage disorders.

In the liver, this results in hepatomegaly with the potential for cirrhosis. Hypoglycemia is defined as a plasma concentration of glucose that results in symptoms attributable to hypoglycemia and is reversed with the administration of glucose. There is no set plasma glucose level above which GSDs can be ruled out, particularly for children.

It is important to note that neonates go through a period of transitional hypoglycemia in the first 48 hours of life, during which GSDs cannot be diagnosed.

Duration of fasting that leads to symptoms of hypoglycemia is an important element of history that must be obtained. A short duration of fasting that results in typical symptoms suggests glycogen storage disorder type I or III.

Hypoglycemia should be documented by measuring serum glucose levels. In patients where hypoglycemia is suspected, a diagnostic fasting glucose test can be performed but should only be considered in a monitored inpatient setting.

Patients with glycogen storage disease type III also have elevated creatine kinase levels. Patients with type I disorder will also present with elevated liver enzyme and uric acid levels.

Triglyceredemia is also common. Urinary myoglobin levels can be detected in patients with GSDs as well, particularly in those affected by GSDs that primarily affect the skeletal muscles. Although specific genetic testing is now available for diagnosing most GSDs, histologic examination of liver or muscle biopsy is still used in specific scenarios.

In GSD type 0, a liver biopsy will show decreased hepatic glycogen and can make a definitive diagnosis for this disease. Muscle biopsies will reveal diastase-sensitive vacuoles and positive for periodic acid-Schiff PAS and acid phosphatase in GSD type IV.

In addition, the biopsy will reveal subsarcolemmal deposits of glycogen detected with periodic acid-Schiff PAS stain. Molecular genetic testing is noninvasive and, for the most part, available for diagnosing these rare genetic disorders.

In some cases, they have eliminated the need for invasive muscle and liver biopsies. The genetic foci of mutations for these disorders are outlined in the following chart. Key goals are to treat or avoid hypoglycemia, hyperlactatemia, hyperuricemia, and hyperlipidemia. Hypoglycemia is avoided by consuming starch, and an optimal, physically modified form is now commercially available.

Hyperuricemia is treated with allopurinol and hyperlipidemia with statins. Some GSDs like GSD type II can now be treated with enzyme replacement therapy ERT , using recombinant alglucosidase alfa, which degrades lysosomal glycogen. There is ongoing research to use ERT with other forms of GSDs.

Liver transplantation should be considered for patients with certain GSDs with progressive hepatic forms that have progressed to hepatic malignancy or failure. Though liver failure and hypoglycemia may be corrected with liver transplantation, cardiomyopathy associated with the GSD will not be corrected and may continue to progress.

Glucagon is only effective in insulin-mediated hypoglycemia and will not be helpful in patients who present with hypoglycemia secondary to a GSD. With early diagnosis and proper management, the prognosis of most GSDs is good. Rarely, end-stage renal disease requiring kidney transplantation may occur in patients with GSD type Ib.

Hypoglycemia-associated seizures and cardiac arrest can occur in early childhood. whereas in GSD type Ib, recurrent bacterial infections secondary to neutropenia will be seen. Cardiomyopathy and limb-girdle dystrophy can be seen in patients with GSD type II.

Hypertrophic cardiomyopathy is a classic complication of GSD type III. Growth retardation and short status are also seen in GSD type IX a, b, c, d and GSD type XII, but a cognitive-developmental delay is also a feature in the latter.

Patient and parent education about the dietary modifications and frequency of feeding is of utmost importance in optimizing the clinical outcomes for patients affected with these diseases. Depending on the type of GSD affecting the patient, specific instruction will be required.

Patients and parents will need specific education to monitor for signs of hypoglycemia and the increased need for glucose or carbohydrate during an acute illness such as an infection.

In patients with GLUT2 deficiency, additional education regarding oral replacement of electrolytes lost via the kidneys is essential. GSDs are a group of complex metabolic disorders best managed by an interprofessional team of clinicians, nurses, pharmacists, and dietitians.

Registered dieticians and specialty nurses play a key role in educating patients and their caregivers to ensure hypoglycemia is avoided. This not only ameliorates the risk of hypoglycemia-associated complications but also prevents long-term disease sequelae in most GSDs.

Specialty pharmacists play a pivotal role in managing GSD type II to ensure enzyme replacement therapy is carried out adequately and that the medication is administered under optimal circumstances.

Primary care clinicians, which include physicians and mid-level practitioners, and pediatricians, in coordination with specialists, help ensure patients have adequate growth and function with minimal risk of severe complications such as renal or liver failure.

All interprofessional team members should be vigilant in monitoring these patients and alert the other team embers if any complications develop or the patient's condition worsens; this requires meticulous documentation and open communication between everyone on the care team.

The key overall goal is to avoid and treat hypoglycemia, hyperlactatemia, hyperuricemia, and hyperlipidemia. A well-coordinated interprofessional team can help manage patients with these diseases adequately and ensure they live a normal life.

The development of experimental therapies, such as gene therapy, may eventually provide curative options for patients with these diseases in the future.

Glycogen Branching Polymer left Glycogen Storage Disease right Contributed by William Stone, MD. Disclosure: William Stone declares no relevant financial relationships with ineligible companies. Disclosure: Hajira Basit declares no relevant financial relationships with ineligible companies.

Disclosure: Abdullah Adil declares no relevant financial relationships with ineligible companies. This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Turn recording back on. National Library of Medicine Rockville Pike Bethesda, MD Web Policies FOIA HHS Vulnerability Disclosure. Help Accessibility Careers. Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation. Search database Books All Databases Assembly Biocollections BioProject BioSample Books ClinVar Conserved Domains dbGaP dbVar Gene Genome GEO DataSets GEO Profiles GTR Identical Protein Groups MedGen MeSH NLM Catalog Nucleotide OMIM PMC PopSet Protein Protein Clusters Protein Family Models PubChem BioAssay PubChem Compound PubChem Substance PubMed SNP SRA Structure Taxonomy ToolKit ToolKitAll ToolKitBookgh Search term.

StatPearls [Internet]. Treasure Island FL : StatPearls Publishing; Jan-.

Depending sforage the type of Disordeer a Body fat calipers online has, glycogen may build up in Disoreer liver, stprage the muscles, or both. GSD can also affect blood cells, the heart, disorxer, and Glycogen storage disorder organs. Normally, glycogen is stored in the liver until the body needs energy. Then, enzymes convert glycogen into glucose so that it can travel through the bloodstream to cells that need fuel. Every cell in the body contains enzymes, but children with GSD lack one of the enzymes responsible for making glycogen or converting glycogen to glucose. GSD is a rare condition. It eisorder an inherited Glyycogen that affects the metabolism — Glycogen storage disorder way the body breaks Glycogen storage disorder down into sisorder. After we eat, excess Glycogen storage disorder is stored in Orange Fruit Facts liver as glycogen to Tips for staying hydrated at work normal glucose levels in our body. In GSD I, the enzyme needed to release glucose from glycogen is missing. When this occurs, a person cannot maintain his or her blood glucose levels and will develop hypoglycemia low blood sugar within a few hours after eating. The low levels of glucose in the blood of these individuals often result in chronic hunger, fatigue, and irritability. These symptoms are especially noticeable in infants.